Dermed Centrum Medyczne Sp. z o.o. — Clinical Trial Site

45 Registered trials

14 Currently recruiting

Organisation

Dermed Centrum Medyczne Sp. z o.o.

Location

Lodz, Poland

Identifier

ORG-100041258

Address

Ul. Piotrkowska 48, 90-265, Poland

Departments

"DERMED" Centrum Medyczne Sp. z o.o.
„DERMED” Centrum Medyczne Sp. zo.o.
/
#40625; Clinical Trials Department
#40625; Dermatology
#40625: DERMED Centrum Medyczne Sp. z o. o.
#45004:Niepubliczny Zaklad Opieki Zdrowotnej "DERMED" Centrum Medyczne
40625: Clinical Trials Department
40625: Dermatology
Dermatology
Dermed Centrum Medyczne
DERMED Centrum Medyczne Sp. z o.o.
DERMED Centrum Medyczne Sp. zo.o.
N/A
N/A. Private institution
NA
Niepubliczny Zakład Opieki Zdrowotnej "DERMED" Centrum Medyczne
not applicable

Clinical trials at this site (45)

Search interface

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended

2023-504447-14-00 Treatment of pediatric subjects with moderate to severe 10 2021-07-29
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 5 2021-01-11
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants Ended

2023-503378-19-00 Chronic Plaque Psoriasis 5 2018-08-23
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended

2023-509425-53-00 Atopic Dermatitis 5 2015-11-09
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A clinical trial to evaluate safety, efficacy, and tolerability of abrocitinib in subjects with chronic hand eczema. Ended

2023-504539-42-00 Moderate to severe chronic hand eczema 4 2024-10-20
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511360-87-00 hidradenitis suppurativa (HS) 5 2024-10-02
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29
Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended

2022-503160-33-00 Hidradenitis Suppurativa 5 2023-12-15
A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended

2022-502370-17-00 Hidradenitis suppurativa 4 2023-11-14
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended

2022-501476-25-00 Atopic Dermatitis Eczema 5 2023-09-12
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic … Ended

2024-514405-65-00 Atopic Dermatitis 4 2021-11-22
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
A study to learn how safe bimekizumab, how well it works and how it moves through the bloodstream in adolescents with moderate to severe pla… Ended

2023-509832-24-00 Moderate to Severe Plaque Psoriasis 4 2021-08-30
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea… Ended

2023-504156-10-00 Plaque Psoriasis. 5 2021-08-13
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12
A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended

2023-508955-37-00 Moderate to severe atopic dermatitis 5 2018-10-10